GBI Research, a leading business intelligence provider, has released its latest research report “Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth”. The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market and commanding greater value compared to the therapies already in the market. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. View full Report With TOC: http://www.reportsandintelligence.com/chronic-obstructive-pulmonary-disease-copd-to-2019-highly-priced-new-combination-products-forecast-to-capture-significant-share-and-drive-growth-market
Download Sample Brochure @ http://tinyurl.com/zbyllyq Marketintelreport’s, ‘Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2015’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects.
Download Sample brochure@ http://tinyurl.com/zbr9qy7 Marketintelreports, ‘Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.
RnRMarketResearch.com adds “Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2015” to its store. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages.
Research Beam added a report on “Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation” Enquiry about report: http://www.researchbeam.com/frontier-pharma-chronic-obstructive-pulmonary-disease-copd-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
Global Market Insights Inc. adds Global Respiratory Disease Testing Market Report focuses on the major drivers and restraints for the Global key players. It also provides analysis of the market share, segmentation, revenue forecasts and geographic regions of the market.
Stay up-to-date with latest Insights of Chronic Disease Management market research offered by Allied Market Research. Check how key trends and emerging drivers are shaping this industry growth.
The global prefilled syringes market attained a value of $1,914.1 million in 2020, and it is predicted to progress at a CAGR of 6.8% between 2021 and 2030. Furthermore, the market is predicted to reach a revenue of $3,646.7 million by 2030. The factors fueling the expansion of the market are the surging concerns raised over the prevalence of needlestick injuries, various advantages of prefilled syringes over conventional vial and syringe packaging systems, and the burgeoning requirement for point-of-care administration.
Chronic disease management (CDM) is ongoing care and support to assist individuals impacted by a chronic health condition with the medical care, knowledge, skills and resources they need to better manage on a day to day basis. It is primarily provided by various software and services. Chronic disease management assists in reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care.
The chronic disease management market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 15.8% in the forecast period of 2021 to 2028 and is expected to reach USD 14,329.15 million by 2028. Rising prevalence of chronic diseases demands the advanced chronic disease management solutions and services, thus acts as driver for the chronic disease management market growth.
The global medical enzymes market is anticipated to grow at a CAGR of 6.56%, and is anticipated to reach $7760.23 million by 2030. Get a Free Sample Report.
The Smart Inhalers in healthcare market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide.
Chronic disease management is an integrated care approach to managing the illness, which includes screenings, check-ups, monitoring and coordinating treatment, and patient education. It can improve the quality of life while reducing healthcare costs. Chronic disease is generally considered a condition that lasts one year or more, requires ongoing medical attention, and/or limits a person’s daily activities. Some of the most common chronic conditions are; heart disease, hypertension (high blood pressure), chronic respiratory disease, diabetes, asthma, stroke, cancer, and others.
Chronic disease management (CDM) is ongoing care and support to assist individuals impacted by a chronic health condition with the medical care, knowledge, skills and resources they need to better manage on a day to day basis. It is primarily provided by various software and services. Chronic disease management assists in reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care.
Market Research Future (MRFR) has published a research report about the global chronic obstructive pulmonary disease (COPD) market that measures huge elevation in this market between 2016 and 2022
obstructive lung disease characterized by long-term breathing problems and poor airflow. When a disease becomes common, and the number of people suffering from it
The global pulmonary devicesmarket,based on type, is segmented into therapeutic devices, consumables and accessories, diagnostic devices, and monitoring devices.The therapeutic devicessegment held the largest share of the market in 2019, and this growth is ascribed tothe increasing demand of inhalers and nebulizers by patients suffering with asthma and chronic obstructive pulmonary disorders.
Respiratory Disease Testing/Diagnostics Market size in 2019 is estimated to be $5.9 billion, growing at a CAGR of 5% during the forecast period 2020-2025. Respiratory disease is the disease that affects the lungs and respiratory system. It is caused by infection, smoking tobacco, or air pollution. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are some of the major respiratory diseases. The growing geriatric population with respiratory disorders and technological advancement in respiratory diagnostic testing are the major factors driving the growth of the market.
Global smart inhalers market size is expected to reach $2.36 Bn by 2028 at a rate of 9.8%, segmented as by type, dry powdered inhalers (dpis), metered dose inhalers (mdis)
Global respiratory disease testing market size is expected to reach $4.31 Bn by 2028 at a rate of 4.8%, segmented as by test type, imaging tests, mechanical tests, in-vitro diagnostic tests
Respiratory Disease Testing Market should witness substantial growth due to increased prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma over the last few years. Increasing pollution and tobacco consumption coupled with rising geriatric population base and technological advancement in respiratory devices should drive respiratory disease testing market size over the forecast period.
According to our latest study on “Pulmonary Devices Market Forecast to 2027– COVID-19 Impact and Global Analysis– by type, application, and end user,”the market was valued at US$ 18,598.56 million in 2019 and is projected to reach US$ 39,965.01 million by 2027; it is expected to grow at a CAGR of 10.1% during 2020–2027. The report highlights trends prevailing in the global pulmonary devices market,and the drivers and hindrances pertaining to the market growth.
Global manual resuscitators market is expected to rise to an estimated value of USD 630.07 million by 2026, registering a steady CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing incidences of chronic obstructive pulmonary diseases in the global population.
The Oxygen Therapy Devices Market is expanding rapidly, due to several major factors. First and foremost, the rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and sleep apnea is a significant driver, owing to factors such as air pollution, smoking, and an aging population. The need for oxygen therapy devices and services has increased as these illnesses grow more common.
Global Pulmonary Drug Delivery Systems Market is expected to grow at CAGR of 6.2% from 2017 to 2025. The report highlights the key trends, market outlook and the global scenario of the Global Pulmonary Drug Delivery
Idiopathic Pulmonary Fibrosis Market size is estimated to reach $4.7 billion by 2027, growing at a CAGR of 7.2% during the forecast period 2022-2027. Idiopathic pulmonary fibrosis (IPF) is a severe incessant ailment that influences the tissue surrounding the air sacs, or alveoli, in the lungs.
Global lower respiratory tract therapeutics market size is expected to reach $48.37 Bn by 2028 at a rate of 7.8%, segmented as by disease type, asthma, chronic obstructive pulmonary disease, pneumonia, tuberculosis, bronchitis, other diseases
Pulmonary Devices Market was valued at US$ 18,598.56 million in 2019 and is projected to reach US$ 39,965.01 million by 2027; it is expected to grow at a CAGR of 10.1%from 2020 to 2027. Get PDF Sample Copy @ https://bit.ly/3rh68He
Pulmonary Drug Delivery Market & Clinical Pipeline Insight @ http://www.reportsnreports.com/reports/285693-pulmonary-drug-delivery-market-clinical-pipeline-insight.html The pulmonary technology offers an exclusive and inventive alternative for drug delivery as it allows for a systemic delivery of large and small molecule drugs through inhalation into the lungs. This mode of drug delivery have helped in reducing the adverse effects of low solubility and absorption of drugs which are present in the other therapies through the oral, intravenous and injection routes.
North America was the largest region in the respiratory diseases drugs market in 2017, accounting for 48% market share. Read Report https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2018
Global Pulmonary Function Testing Market expected to rise from its initial estimated value of USD 367.88 million in 2018 to an estimated value of USD 691.07 million by 2026 registering a CAGR of 8.2% in the forecast period of 2018-2026. This rise in the market can be attributed to the increasing prevalence of lung cancer, rapidly increasing geriatric population, obesity and increasing healthcare expenditure.
Mobile health (mHealth) is a branch of electronic health (eHealth) that delivers revolutionized healthcare service in which communication devices are used for the remote monitoring of patients suffering from acute and chronic diseases. mHealth majorly involves the use of mobile and wireless technologies, which are deployed in monitoring and treatment of several diseases.
Bharatbook.com announces a new report on "Pulmonary Drug Delivery Market & Clinical Pipeline Insight", The demand for new and innovative drug delivery systems has been on a rising trend with the pharmaceutical companies concentrating on developing innovative methods for this area.
The global pulmonary/respiratory drug delivery market is expected to reach USD 63.79 billion by 2025, from USD 38.63 billion in 2017 growing at a CAGR of 6.7% during the forecast period of 2018 to 2025.
In the recent past, the global nebuliser market has been on a steady upward trajectory. These nebulisers are widely used to treat cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). For More Information of Nebuliser Market Visit: https://www.fairfieldmarketresearch.com/report/nebuliser-market
The respiratory care device market is growing year on year due to changing lifestyle, and environmental condition such as pollution, rising geriatric population, increasing number of smokers, growth in the number of chronic obstructive pulmonary disease patients.
Mechanical ventilator, sometimes also known as ventilator, breathing machine or respirator, is a device which is used by healthcare institutions and hospitals in the management of patient’s breathing problems. Usage of mechanical ventilation process is the last choice for a patient who is suffering from breathing problems and cannot maintain adequate oxygenation to maintain life. Mechanical ventilation process is mainly used in the treatment of chronic obstructive pulmonary disease (COPD), apnea, acute lung injury and hypoxemia. Globally, increasing incidences of chronic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and other lunch disorders are expected to remain key growth drivers for the mechanical ventilation & accessories market during the period of study.
Respiratory Disease Testing Market should witness substantial growth due to increased prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma over the last few years. Increasing pollution and tobacco consumption coupled with rising geriatric population base and technological advancement in respiratory devices should drive respiratory disease testing market size over the forecast period.
“Tracheostomy Products Market” Report will provide important aspects with overall outlook of the market worldwide, According to Adroit Market Research.
Increase in prevalence of target diseases including diabetes, asthma, chronic obstructive pulmonary disorder (COPD), and cardiovascular diseases coupled with rapid technological advancements in drug delivery devices are key factors driving the global electronic drug delivery systems market.
The latest report on Vital Signs Monitoring Devices Market by Infinium Global Research gives complete coverage of the Vital Signs Monitoring Devices Market by product type (body temperature, blood pressure, pulse oximeters), by end- user (ASCs, hospitals), by region (Americas, Europe, Asia-Pacific, Rest of the World (RoW)) in terms of key trends, market size, forecast and CAGR growth over the period of 2017 to 2023. In addition, the study covers deep dive into key product and applications trends in the regional markets of Vital Signs Monitoring Devices such as North America, Europe, Asia-Pacific and Latin America over the short run and long run.
Dry Powder Inhaler Market By Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Cardiovascular Disease, Diabetes , Others) By Type (Single dose, Multi-dose) By End-User (Hospitals & Clinics, Homecare) and Region - Global Forecast 2016 to 2024
This research report titled “Global Respiratory Care Medical Devices Market: Size, Trends & Forecasts (2018-2022)”, provides an in-depth analysis of the global respiratory care medical devices market with description of market sizing and growth. The analysis includes market by value and market share by region, by product-type, and by disorders. An analysis of product analysis has also been provided in the report. Complete report on Respiratory Care Medical Devices market spread across 77 pages with providing 4 company profiles, 2 tables and 33 figures is now available at http://www.marketreportsonline.com/781837.html.
The world mechanical ventilators market is estimated to garner $3.9 billion by 2022, with a CAGR of 5.4% from 2016 to 2022. The increasing incidence of chronic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and other lunch disorders, and increasing number of accidental emergencies lead to the substantial requirement of mechanical ventilators. In addition, growing geriatric population prone to respiratory emergencies is one of the key drivers of the market. Read more details @ https://www.alliedmarketresearch.com/mechanical-ventilators-market
The U.S. air purification equipment market was valued at USD 7.52 billion in 2017 and is expected to grow at a lucrative rate on account of increasing awareness regarding health hazards such as asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases.
Asthma & COPD Drugs Market size is estimated to reach $42.1 billion by 2027, growing at a CAGR of 4.7% during the forecast period 2022-2027. Asthma & COPD Drugs have the principal goal to reverse bronchoconstriction which is hindering the airway to enhance air flow in and out of the lungs. Bronchodilators are principal in the treatment of airways ailments. They are the backbone of the present handling of chronic obstructive pulmonary disease (COPD) and are crucial in the symptomatic handling of asthma, though controversies around the application of these medications prevail.